ObjectiveHealth – a leading integrated specialty research network and technology company – announced that it has secured a strategic growth investment from Vitruvian Partners, a leading global growth-focused investment firm.
ObjectiveHealth is considered an innovator in clinical research, seamlessly integrating clinical trials into physicians’ practices while deploying proprietary advanced technology to identify and recruit patients for the trials.
Vitruvian’s investment will provide the capacity for ObjectiveHealth to expand its operations and continue its rapid pace of growth.
ObjectiveHealth’s AI-driven technology utilizes patients’ electronic health record data and the provider schedule to quickly identify candidates for specific clinical trials while providing a platform to manage trial workflow more efficiently. Along with trained research coordinators located in the footprint of partner practices, ObjectiveHealth offers clinical trials as a natural extension of the patient care process, creating centers of excellence in community-based specialty practices.
As part of ObjectiveHealth’s continued expansion, last year alone the company:
– Opened its 30th research center-of-excellence in Amarillo, Texas.
– Launched ObjectiveScreen, an AI-powered feasibility and recruitment platform to optimize clinical trial performance.
– Unveiled ObjectiveView, which is a technology portal that provides the sponsors of clinical trials with an unprecedented level of transparency in the process.
– Continued to expand its research portfolio into dermatology, urology and oncology in addition to gastroenterology at its partnered research sites nationwide.
KEY QUOTES:
“As we move into the age of precision medicine, clinical research will be increasingly vital to the future of healthcare and, at ObjectiveHealth, we’re uniquely positioned to provide needed solutions for modernizing and elevating the trial process. We are delighted to have gained the partnership of Vitruvian, whose team has a wealth of knowledge in supporting the rapid growth in companies like ObjectiveHealth.”
– Colleen Hoke, co-founder and CEO of ObjectiveHealth
“These are exciting times for clinical research, and ObjectiveHealth is at the forefront of delivering a new research model that helps address some of our industry’s biggest challenges, while supporting our physician partners in bringing new care solutions to patients in communities we serve. We’re grateful for Vitruvian’s support as we undertake the next phase of our company’s expansion.”
– Dr. Don Lazas, co-founder and chief medical officer at ObjectiveHealth
“Under Colleen and Don’s leadership, ObjectiveHealth has built an innovative and disruptive platform for advancing clinical research. As clinical research continues to converge with healthcare, we believe our investment will give ObjectiveHealth the resources to further develop its technology, broaden its reach into new regions and deliver more treatment options for patients.”
– Sophie Bower-Straziota, partner at Vitruvian
“It has been a privilege partnering with Colleen, Don and the ObjectiveHealth team to expand the reach of and access to clinical research through their novel approach to partnership with specialist physician practices and community health centers. We look forward to continuing that journey and are excited to see the impact of the knowledge and expertise that the Vitruvian Life Sciences & Healthcare team brings alongside their investment.”
– Austin Poole, partner at BIP Ventures
“Welcoming Vitruvian further validates ObjectiveHealth’s novel clinical research model. They are the perfect partner to support the next phase of growth for the company.”
– Christopher Booker, partner at Frist Cressey Ventures
